Clinical evaluation of thermography in the diagnosis of malignant tumors in the oral and maxillo-facial region

1992 ◽  
Vol 8 (1) ◽  
pp. 11-17 ◽  
Author(s):  
Yasuhiro Hayase ◽  
Toru Wakasa ◽  
Masato Uemura ◽  
Kiyoyuki Adachi ◽  
Satoru Ochi ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Malignant Tumors ◽  
Facial Region

scholarly journals Clinical Evaluation of Immunological Parameters in Patients with Malignant Tumors of Head and Neck

1989 ◽  
Vol 1989 (Supplement33) ◽  
pp. 127-135
Author(s):  
Junichi Yoda ◽  
Tadahito Saito ◽  
Takaaki Kawaguchi ◽  
Hiroki Arai ◽  
Toshihide Tabata
Keyword(s):  
Head And Neck ◽  
Clinical Evaluation ◽  
Malignant Tumors ◽  
Immunological Parameters

CLINICAL-EVALUATION OF SERUM BASIC FETOPROTEIN AS A MARKER IN UROGENITAL MALIGNANT-TUMORS

1995 ◽  
Author(s):  
A GOTOH ◽  
K HARADA ◽  
K GOHJI ◽  
S ARAKAWA ◽  
S KAMIDONO
Keyword(s):  
Clinical Evaluation ◽  
Malignant Tumors ◽  
Basic Fetoprotein

scholarly journals Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

2005 ◽  
Vol 16 (8) ◽  
pp. 1391-1397 ◽  
Author(s):  
S.N. Holden ◽  
S.G. Eckhardt ◽  
R. Basser ◽  
R. de Boer ◽  
D. Rischin ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Egf Receptor ◽  
Malignant Tumors ◽  
Receptor Signaling ◽  
Active Inhibitor ◽  
Orally Active ◽  
Solid Malignant Tumors

scholarly journals Pre-clinical evaluation of [111In]-benzyl-DOTA-ZHER2:342, a potential agent for imaging of HER2 expression in malignant tumors

2007 ◽  
Author(s):  
Anna Orlova ◽  
Thuy Tran ◽  
Charles Widström ◽  
Torun Engfeldt ◽  
Amelie Eriksson Karlström ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Malignant Tumors ◽  
Her2 Expression

P.169 Clinical evaluation of FDG-PET for oral malignant tumors

2008 ◽  
Vol 36 ◽  
pp. S210
Author(s):  
R. Matsubara ◽  
S. Kawano ◽  
K. Oobu ◽  
T. Chikui ◽  
Y. Nakao ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Fdg Pet ◽  
Malignant Tumors

scholarly journals Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

2011 ◽  
Vol 22 (2) ◽  
pp. 431-437 ◽  
Author(s):  
D.S. Boss ◽  
P.O. Witteveen ◽  
J. van der Sar ◽  
M.P. Lolkema ◽  
E.E. Voest ◽  
...  
Keyword(s):  
Clinical Evaluation ◽  
Malignant Tumors ◽  
Aurora B ◽  
Aurora B Kinase ◽  
Solid Malignant Tumors

BONY TUMOURS OF MAXILLOFACIAL REGION : RETROSPECTIVE STUDY OF CLINICO-PATHOLOGICAL PROFILE AND THEIR MANAGEMENT

2017 ◽  
Vol 2 (01) ◽  
Author(s):  
Shubham Dadoo ◽  
Rohit Sharma ◽  
Vineet Sharma ◽  
Annanya Soni
Keyword(s):  
Retrospective Study ◽  
Fibrous Dysplasia ◽  
Malignant Tumors ◽  
Odontogenic Cyst ◽  
Retrospective Data ◽  
Neoplastic Tissue ◽  
Maxillofacial Region ◽  
Facial Region ◽  
Maxillary Region

Introduction: Maxillo-facial tumours are a group of heterogenous diseases that ranges from hamartomas or non-neoplastic tissue proliferations to benign neoplastic to malignant tumors with metastatic potentials. The aim of the present study is to evaluate the clinico-pathological profile and management of primary lesions of facio-maxillary region. Material and Methods: Retrospective data of bony tumors of maxilla-facial region was retrieved for 2 years from March 2015 to April 2017. The data included the gender, age, diagnosis based on radiology, histopathology and the site of origin. Results: A total of 18 patients were diagnosed as a bony tumour of maxillofacial region and treated surgically. Fibrous dysplasia, Odontogenic cyst and Ameloblastoma were the most common lesions. Conclusion: Bony tumours of Maxillofacical region though uncommon and mostly benign, pose a great challenge to preserve the functions and cosmesis.

Sign in / Sign up

Export Citation Format

Share Document